Pacira Biosciences (PCRX) said Monday it settled the litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories related to patents for Exparel.
The parties will file consent judgments with the US Court of Appeals for the Federal Circuit and the US District Courts for the Districts of New Jersey and Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit.
In settlement of all outstanding claims in the litigations, Pacira agreed to provide Fresenius with a license to Pacira's patents to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the US beginning on an undisclosed date in early 2030.
The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of Pacira's Orange Book-listed patents for Exparel.
Exparel is a local analgesic used to decrease sensation in a small area post surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.